🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — October 02, 2026

The 36 filings from Dow 30 constituents reveal a period of muted insider activity and routine director compensation, with only a few high-conviction signals. The most material development is NIKE's mixed Q1 FY27 earnings, showing a 4.3% YoY revenue decline and a 39.2% drop in operating cash flow, signaling ongoing demand and working capital pressure. Insider selling by the CEOs of Visa and Walmart, both under 10b5-1 plans, provides a bearish undercurrent, while a CFO at 3M exercised a significant option position, indicating management confidence. The bulk of filings are routine director stock awards across Disney, American Express, Walmart, and McDonald's, which are neutral from a trading perspective. No forward-looking guidance changes were explicitly flagged in the enriched data, but the lack of bullish insider buying across the index suggests a cautious management outlook. The key portfolio-level theme is a divergence between consumer discretionary (NIKE weakness) and consumer staples (Walmart insider selling), with financials (Visa CEO sale) also showing a bearish tilt.

35 high priority 1 medium 36 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 02, 2026

All 8 filings in this digest signal acute distress across US-listed micro-cap companies, with 8/8 receiving delisting or deficiency notices from Nasdaq or NYSE American within a single week (September 28-October 1, 2026). The dominant theme is a liquidity crisis: 6 companies failed the $1.00 minimum bid price rule, one failed the $35M MVLS requirement, and one was delisted for low selling price. Notably, 3 companies (Amaze, Direct Digital, Healthcare Triangle) face imminent trading suspensions, with Healthcare Triangle ineligible for standard cure periods due to two reverse splits totaling 1-for-14,940—a hallmark of chronic price decay. The cluster of identical compliance deadlines (March 29, 2027) suggests a systemic wave of micro-cap distress, likely driven by sustained selling pressure and weak fundamentals. No period-over-period financial data or insider activity was disclosed in these filings, limiting quantitative trend analysis, but the absence of any bullish signals underscores the severity. The most critical near-term catalyst is Healthcare Triangle's October 8 appeal deadline, which will determine whether it faces immediate suspension. Investors should treat these as high-risk situations with limited upside, though potential reverse-split-driven compliance and OTC market transitions create speculative trading opportunities.

8 high priority 8 total filings
· daily

Global High-Priority Regulatory Events — October 02, 2026

This digest synthesizes 37 enriched SEC filings from October 2, 2026, covering critical market events including delistings, business combinations, tender offers, and regulatory actions. Key themes include a wave of SPAC and de-SPAC activity with dilutive financing structures, a cluster of delisting notices driven by bid price and market value non-compliance, and continued capital markets stress in micro-cap and distressed issuers. Notable transactions include EchoStar's $4.35B debt restructuring, a $400M all-stock SPAC merger in rare earths, and multiple closed-end fund tender offers. The digest highlights 10 investment signals, 8 risks, 8 opportunities, and 5 sector themes, with a focus on actionable intelligence from period comparisons, insider activity, and forward-looking guidance.

37 high priority 37 total filings
· daily

US SEC Filings Daily Market Digest — October 02, 2026

Today's filings reveal a market bifurcated between aggressive capital deployment and operational caution. A major theme is the surge in M&A and strategic pivots, with CareTrust REIT's £1.1B UK acquisition and Flowco's $113M deal signaling confidence in real assets and energy services. Conversely, consumer-facing companies like Nike and Dogness are showing clear signs of strain, with revenue declines and margin compression. The insider trading activity is sparse but notable, with Alibaba's Chief People Officer selling $12M in stock, a potential bearish signal. The capital markets are active with several SPAC and PIPE deals, while the biotech sector shows a mixed picture of clinical progress and financial distress. The forward-looking data points to several key catalysts in Q4 2026 and Q1 2027, including the Utz Brands going-private vote and the Scully Royalty EGM, creating a defined calendar of events for investors.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 02, 2026

This digest covers 10 filings from the S&P 500 Consumer Discretionary sector, with 5 new filings (NIKE 10-Q, Ford 8-K, Tesla 8-K, and 3 MGM Form 4s) and 5 previously covered filings (2 MGM Form 4s, 3 McDonald's Form 4s). The dominant theme is a mixed picture for consumer spending: NIKE's revenue decline (-4.3% YoY) and working capital pressure contrast with Tesla's strong Q3 delivery beat (486,532 vehicles vs. production of 464,391) and positive sentiment. Ford's F-150 production disruption is contained within guidance, but adds near-term uncertainty. Insider activity is limited to routine director awards and a tax-withholding sale by an MGM executive, providing no strong conviction signals. Capital allocation trends show NIKE reducing debt and maintaining buybacks, while Tesla's delivery surge sets up a potential earnings beat. The sector is bifurcated: premium/EV demand (Tesla) is robust, while legacy retail (NIKE) faces demand normalization. Key catalysts include Tesla's Q3 earnings on Oct 21 and Ford's Q3 report.

10 high priority 10 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 02, 2026

The October 2, 2026, digest of 16 S&P 500 Healthcare filings is dominated by routine director compensation awards (equity grants) and a single insider sale, offering limited actionable trading signals but revealing important capital allocation and governance patterns. Across Abbott Laboratories, Bristol-Myers Squibb, and AbbVie, 12 directors received stock equivalent or deferred share units, signaling a standardized, non-discretionary compensation structure with no insider conviction signals. The most material event is Gilead Sciences' CEO Daniel O'Day selling $2.22M in stock under a 10b5-1 plan, which, while pre-planned, reduces his holdings by 2.6% and warrants monitoring for future conviction. Zoetis' EVP Julie Fuller executed a net tax-withholding sale after vesting, a routine transaction. The key strategic development is Medtronic's Form 425 filing detailing its MiniMed separation exchange offer, a major corporate action that will unlock shareholder value and create a pure-play diabetes entity. No period-over-period financial trends, guidance changes, or capital allocation actions (dividends, buybacks) were present in these filings, making the digest's primary value the identification of upcoming catalysts and the assessment of insider behavior.

16 high priority 16 total filings
· daily

US Earnings Financial Results SEC Filings — October 02, 2026

The 8 filings reveal a stark divergence between consumer-facing and industrial/commodity sectors. Consumer discretionary companies like Darden Restaurants and NIKE are showing revenue growth but margin compression, while homebuilder Lennar and specialty retailer iPower are experiencing severe revenue and profit declines. The lone bright spot is Trilogy Metals, which swung to a quarterly profit on derivative gains, though its core investment continues to drain cash. Capital allocation patterns show increased buybacks at Darden and NIKE despite operational headwinds, while Lennar's cash position collapsed 62% QoQ. Insider activity is notably absent across all filings, which is itself a signal of management caution. The most critical development is the 52% YoY earnings collapse at Lennar, which may signal broader housing market weakness, while iPower's 68% revenue decline raises existential questions about its business model.

8 high priority 8 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 02, 2026

The 21 filings in this executive compensation digest reveal a period of significant corporate restructuring and shareholder value events. A dominant theme is the wave of M&A and liquidation proposals, with Utz Brands, MarineMax, and Steele Creek Capital all seeking shareholder approval for going-private or dissolution transactions, signaling a potential peak in private equity interest and a lack of confidence in public market valuations. Governance is under the spotlight, with Fermi Inc. terminating its CEO for cause and Oaktree Acquisition Corp. III Life Sciences and Chain Bridge I seeking repeated extensions, highlighting execution risks in the SPAC space. Financially, Adtalem Global Education stands out with strong 9.3% revenue growth and 23.7% adjusted EPS growth, while Jack Henry & Associates shows steady performance with 22 consecutive years of dividend increases. However, the Tax-Free Fixed Income Funds for Puerto Rico Residents are liquidating due to high expense ratios and governance disputes, underscoring the challenges in closed-end fund structures. Overall, the period is characterized by a mix of value realization events and governance red flags, with a clear trend toward consolidation and capital return to shareholders.

21 high priority 21 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 02, 2026

On October 2, 2026, nine SEC filings revealed a dense IPO pipeline, dominated by six initial public offerings and registration statements, alongside three merger-related S-4 filings. The day’s filings signal a surge in capital formation, particularly among clinical-stage biotech (HCW Biologics, Sunshine Biopharma), early-stage technology (Vertical Data), and specialty healthcare (BioStem Technologies) companies, many of which carry high risk due to pre-revenue status, accumulated deficits, or dilution-heavy capital structures. Aggregate period-over-period data shows that the combined pro forma entity from the John Marshall Bancorp merger would have generated $74.2M in net interest income (up 111% from JMSB standalone), while HCW Biologics remains pre-revenue with an accumulated deficit of -$168.2M. Key patterns include a notable reliance on non-traditional listing methods (direct listing for Georgia Banking Co.), heavily dilutive warrant structures, and distinct geographic concentration in the mid-Atlantic and Hong Kong-based blank check SPAC. The absence of meaningful insider trading activity in these pre-public companies limits conviction signals, but forward-looking disclosures point to material catalysts—including a Phase 1 readout and a critical Nasdaq compliance decision—that frame near-term risk/reward.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — October 02, 2026

This digest covers 8 regulatory filings from October 2, 2026, all involving trading suspensions or delistings on US exchanges (NYSE American and Nasdaq). The dominant theme is a wave of micro-cap and pre-revenue companies failing to maintain minimum bid price or market value standards, with 6 of 8 filings triggered by sub-$1.00 bid prices. Notably, Healthcare Triangle faces an expedited delisting due to two reverse stock splits in two years, while Direct Digital Holdings and Amaze Holdings have already received final delisting notices with no appeal. The cluster of filings on September 28-29, 2026, suggests a coordinated exchange compliance review. No period-over-period financial data, insider activity, or capital allocation metrics were available in these filings, limiting quantitative trend analysis. The materiality is uniformly high (8-10/10), as delisting from a major exchange to OTC Pink or similar severely impairs liquidity and capital access. The key forward-looking dates cluster around March 29, 2027, for compliance deadlines, creating a catalyst calendar for investors to monitor.

8 high priority 8 total filings
· daily

US Executive Officer Management Changes SEC — October 02, 2026

This digest covers 43 executive and director change filings from October 2, 2026, revealing a period of significant leadership turnover across sectors. A dominant theme is planned succession and board restructuring, with several companies (Seritage, Aimco, Nocopi) implementing transition periods and consulting arrangements to ensure continuity. Notably, compensation adjustments are prevalent, with Starfighters Space approving a 224% CEO salary increase and Live Nation extending its CEO's contract through 2031 with a $40M annual equity grant, signaling strong retention efforts. Board shakeups are material at Hub Group (three directors removed by stockholder consent) and Quince Therapeutics (three directors conditionally resigning). The data also shows a clear trend of companies appointing directors with specific expertise, such as mineral exploration at Klotho Neurosciences and former UK PM Liz Truss at RTB Digital, indicating strategic pivots. Overall, while most filings are neutral in sentiment, the high volume of changes suggests a dynamic corporate governance landscape with potential for both disruption and strategic realignment.

43 high priority 43 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 02, 2026

This batch of 43 filings reveals a significant wave of board and C-suite changes across US-listed companies, with a notable concentration of planned successions and departures effective October 1, 2026. A key theme is the prevalence of 'neutral' sentiment filings, indicating routine transitions rather than performance-driven upheaval, though several high-materiality events stand out. The most impactful developments include a major board shakeup at Hub Group (materiality 7/10) driven by stockholder action, a leadership transition at Hines Global Income Trust (materiality 6/10) signaling a generational shift, and the appointment of a former UK Prime Minister to the board of RTB Digital (materiality 3/10). While enriched data on period-over-period financial trends is largely absent from these filings, the insider activity and forward-looking statements provide actionable intelligence, particularly around the CEO extension at Live Nation (materiality 6/10) and the commercial-stage transition at Celcuity (materiality 6/10). The overall pattern suggests a period of governance recalibration, with several companies strengthening independent board representation and aligning executive compensation with performance metrics.

43 high priority 43 total filings
· daily

USA Insider Trading Pulse — October 02, 2026

The October 2, 2026, insider trading pulse reveals a market dominated by routine, non-discretionary transactions, with 42 of 50 filings representing scheduled awards, tax withholdings, or phantom stock grants. This high volume of neutral, low-materiality activity creates significant noise, masking the two critical, high-conviction signals of the day: a $1.09M sale by Keysight Technologies' CEO and a $12M sale by Alibaba's Chief People Officer. These two insider sales, representing the only material bearish signals, suggest potential concerns at the executive level within the technology and Chinese ADR sectors. A notable cluster of insider awards at Republic Bancorp and director compensation at TREDEGAR CORP and IES Holdings indicates standard corporate governance cycles. The most actionable intelligence lies in the divergence between the routine awards and the significant, voluntary sales by top executives, which warrant close monitoring for any follow-on transactions or guidance changes.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 02, 2026

The 12 filings reveal a dynamic M&A landscape with a heavy SPAC presence (6 of 12 filings) at various stages—from IPO (Bluerock) to completed business combinations (Columbus/WISeSat) to pending deals with complex PIPE financing (Piermont). Notable large-scale acquisitions include CareTrust REIT's £1.1B UK care home purchase and ESCO Technologies' $2.3B Megger acquisition, both cross-border. EchoStar's DISH DBS emerges from Chapter 11 with a $4.35B debt reduction, strengthening its balance sheet. Key trends: SPACs face shareholder redemption risks and regulatory hurdles (Spark I, Hall Chadwick), while PIPE terms become more aggressive with potential dilution (Piermont). Insider activity is minimal across filings, but sponsor changes (Tavia) and management continuity (Hall Chadwick) provide signals. Overall, the period shows robust M&A activity with a mix of opportunistic acquisitions and distressed restructuring, offering both alpha opportunities and risk flags for investors.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 02, 2026

This overnight filing cycle reveals a market bifurcated between aggressive capital deployment and strategic retrenchment. A dominant theme is the surge in M&A and capital allocation, with CareTrust REIT executing a landmark £1.1B UK care home acquisition and Flowco Holdings closing a $113M energy services deal, both raising full-year guidance. Conversely, a wave of insider selling—including a $2.95M disposal by Alto Neuroscience's CFO and a $2.62M sale by Marvell Technology's President—signals potential conviction gaps at the executive level. Period-over-period data highlights acute distress in the pet sector, with Dogness International reporting a net loss of $27.6M, widening from a $5.1M loss, while NIO's vehicle deliveries declined 3.7% YoY despite a QoQ improvement. The most critical development is the proposed going-private of Utz Brands at a 91% premium, offering a clear arbitrage opportunity, while the complete exit of GIC from Claritev Corp and a forced EGM at Scully Royalty point to underlying governance and strategic shifts. The overall picture is one of high-velocity capital rotation, where acquirers are rewarded and laggards face intensified insider skepticism.

32 high priority 18 medium 50 total filings
· daily

HHS & Healthcare Contracts Intelligence — October 01, 2026

This digest analyzes a single $563.7 million HHS contract awarded to Advanced Technology International (ATI) for BARDA-driven pandemic vaccine R&D, representing 100% civilian agency spending. The contract is large and long-duration (11+ years) but early-stage, with only $1.9 million outlaid to date, signaling strong long-term government commitment to biodefense preparedness but minimal near-term revenue impact. ATI’s nonprofit, fixed-price structure introduces margin uncertainty, while the full-and-open competition suggests no single company has a locked-in moat. The neutral signal strength (6/10) and low materiality (5/10) warrant cautious monitoring of future funding obligations rather than immediate action.

1 total filings
· daily

New Federal Contractors — October 01, 2026

The five contracts awarded on October 1, 2026, total $3.83 billion, with only one defense-related award (SAIC’s $526.5M Air Force training contract) and four civilian awards dominated by the Department of Education ($1.75B combined to Nelnet Servicing and Maximus Education) and HHS ($1.55B combined to Palmetto GBA and Advanced Technology International). The highest-conviction signal is Nelnet Servicing’s $988.7M bullish award, where total outlays of $1.64B already exceed the contract value, indicating strong recurring revenue from a stable client. Key risks include fixed-price execution pressure on Nelnet and Maximus, and SAIC’s negative outlayed amount suggesting early-stage execution or scope adjustments.

5 total filings
· daily

Significant Contract Modifications ($10M+) — October 01, 2026

The October 1, 2026 contract modification stream totals $3.83 billion across five awards, with a heavy civilian tilt (4 of 5 contracts) and only one defense-related award. The Department of Education dominates, with Nelnet Servicing ($988.7M) and Maximus Education ($764.4M) securing large fixed-price loan servicing contracts, signaling sustained federal investment in student loan operations. The highest-conviction signal is Nelnet's contract, which has already outlaid $1.64 billion against a $983.7M base, indicating strong revenue visibility and potential scope expansion. Key risks include the fixed-price structure on both Education contracts (execution risk) and the negative outlayed amount on SAIC's AFAMS contract, which may signal early-stage execution or scope adjustments. Watch for re-compete announcements as both Education contracts expire on December 31, 2024, and monitor SAIC's outlay trend for cash flow implications.

5 total filings
· daily

Contract Deobligations Alert — October 01, 2026

The five contracts analyzed total $3.83 billion in obligations, with only one defense-related award (SAIC's $526.5M AFAMS contract via GSA), underscoring a dominant civilian agency theme led by the Department of Education ($1.75B combined to Nelnet Servicing and Maximus Education) and HHS ($1.55B to Palmetto GBA and Advanced Technology International). The highest-conviction signal is the bullish revenue visibility for Nelnet Servicing, whose $983.7M contract has already outlayed $1.64B, indicating scope expansion beyond the base award. A key risk is the expiration of both Education loan servicing contracts on December 31, 2024, creating recompete uncertainty for Nelnet and Maximus. The SAIC contract's negative outlayed amount and heavy subaward pass-through ($477.5M of $529.9M) raise execution and cash flow concerns.

5 total filings
· daily

Contract Option Exercises — October 01, 2026

This digest covers $3.83 billion in contract option exercises from October 1, 2026, with a heavy civilian tilt (4 of 5 contracts) and only one defense-related award. The Department of Education dominates the period, with two large firm-fixed-price delivery orders totaling $1.75 billion awarded to Nelnet Servicing LLC and Maximus Education LLC for direct loan services, both set to expire on December 31, 2024—creating a critical re-compete catalyst. The highest-conviction signal is the $988.7 million Nelnet award, where total outlays of $1.64 billion already exceed the contract value, indicating strong demand and potential scope expansion. Key risks include the fixed-price structure on both Education contracts, which pressures margins, and the negative outlayed amount on SAIC's $526.5 million Air Force training contract, which may signal early-stage execution challenges or scope adjustments.

5 total filings